Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Private Placement
Semnur Announces $20 Million Private Placement at $16.00 per share
Details : The proceeds will be used to advance the second Phase 3 clinical trial for the development of SP-102 (dexamethasone sodium phosphate viscous gel) (SEMDEXA), for the treatment of LRP/Sciatica.
Product Name : Semdexa
Product Type : Steroid
Upfront Cash : Undisclosed
August 21, 2025
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Private Placement
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Denali Capital Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
Semnur to go Public via SPAC Merger with Denali Capital in $2.5 bln Deal
Details : Semnur’s lead program, Semdexa (dexamethasone sodium phosphate), is the first non-opioid novel injectable corticosteroid gel formulation for moderate to severe chronic radicular sciatica.
Product Name : Semdexa
Product Type : Steroid
Upfront Cash : Undisclosed
September 03, 2024
Lead Product(s) : Dexamethasone Sodium Phosphate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Denali Capital Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102
Details : SP-102 is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Radiculopathy.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 03, 2018
Reset All
